[Sar9,Met(O2)11]-Substance P
(Synonyms: 精氨酰-脯氨酰-赖氨酰-脯氨酰-谷氨酰-谷氨酰-苯丙氨酰-苯丙氨酰-SAR-亮氨酸-蛋氨酸[O2]-胺) 目录号 : GC13610
A peptide NK1 receptor agonist
![[Sar9,Met(O2)11]-Substance P Chemical Structure](/media/struct/GC1/GC13610.png "[Sar9,Met(O2)11]-Substance P Chemical Structure")
Cas No.:110880-55-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment: | Rats initially receive an i.c.v. injection of artificial cerebrospinal fluid (aCSF; 1 μl) followed 60 min later by a single dose of either [Sar9,Met(O2)11]-Substance P (10 pmol (n=9), 25 pmol (n=9), 65 pmol (n=8) or 100 pmol (n=8)) or septide (10 pmol (n=12), 25 pmol (n=9), 65 pmol (n=6) or 100 pmol (n=6)) to construct a complete dose-response curve. Each rat is selected randomly and injected with only one of the two agonists for the remainder of the protocol. Increasing doses of [Sar9,Met(O2)11]-Substance P or septide are given at 24 h intervals on day 1 (10 pmol), day 2 (25 pmol), day 3 (65 pmol) and day 4 (100 pmol). Control rats (n=18) receive only the vehicle (aCSF) each day of experiment. Peptides are administered in a volume of 1 μL of vehicle followed by 5 μL flush volume of aCSF which corresponds to the void volume of the catheter. Each dose is calculated per rat in 1 μL solution[1]. |
References: [1]. Cellier E, et al. Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat. Br J Pharmacol. 1999 Jun;127(3):717-28. | |
[Sar9,Met(O2)11]-Substance P is a tachykinin NK1 receptor selective agonist.
[Sar9,Met(O2)11]-Substance P and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet they have dissimilar time-course. Both agonists increase dose-dependently face washing and sniffing while [Sar9,Met(O2)11]-Substance P is the sole to produce grooming[1].
Reference:
[1]. Cellier E, et al. Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat. Br J Pharmacol. 1999 Jun;127(3):717-28.
| Cas No. | 110880-55-2 | SDF | |
| 别名 | 精氨酰-脯氨酰-赖氨酰-脯氨酰-谷氨酰-谷氨酰-苯丙氨酰-苯丙氨酰-SAR-亮氨酸-蛋氨酸[O2]-胺 | ||
| Canonical SMILES | CC(C[C@@](/N=C(O)/CN(C([C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@]1([H])CCCN1C([C@](/N=C(O)/[C@]2([H])CCCN2C([C@](N)([H])CCCNC(N)=N)=O)([H])CCCCN)=O)([H])CCC(O)=N)([H])CCC(O)=N)([H])CC3=CC=CC=C3)([H])CC4=CC=CC=C4)=O)C)([H])/C(O)=N/[C@@](C(O)= | ||
| 分子式 | C64H100N18O15S | 分子量 | 1393 |
| 溶解度 | Soluble to 1 mg/ml in sterile water | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.7179 mL | 3.5894 mL | 7.1788 mL |
| 5 mM | 0.1436 mL | 0.7179 mL | 1.4358 mL |
| 10 mM | 0.0718 mL | 0.3589 mL | 0.7179 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。